A Tertiary Academic Medical Center Blood Bank's Experience With Four-Factor Prothrombin Complex Concentrate
| Autor: | Aaron D Shmookler, Tracie L Nichols, Peter Perrotta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Rivaroxaban Pathology Clinical business.industry Warfarin Transfusion medicine Pharmacy Hemorrhage General Medicine Emergency department 030204 cardiovascular system & hematology Prothrombin complex concentrate Blood Coagulation Factors Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine Emergency medicine medicine Blood Banks Humans Apixaban 030212 general & internal medicine business Blood bank medicine.drug |
| Zdroj: | American journal of clinical pathology. 156(2) |
| ISSN: | 1943-7722 |
| Popis: | Objectives The role of transfusion medicine consultative services in prospectively auditing (PA) orders for four-factor prothrombin complex concentrate (4F-PCC) was evaluated at an academic medical center. Methods Data from 4 years of 4F-PCC orders were obtained from the laboratory information system, and electronic health records of patients receiving concentrate were reviewed. Results 4F-PCC was ordered for 427 patients with warfarin-, apixaban-, or rivaroxaban-associated hemorrhage. Turnaround time (TAT) to prepare 4F-PCC was longer when PA-recommended dose adjustments were needed (85 vs 66 minutes, P = .03). There was no difference in TAT between patients who died and those who were ultimately discharged (60 vs 70, P = .22). TAT was shortest for orders originating in the emergency department (ED) compared with other locations (64 vs 85, P Conclusions PA can ensure 4F-PCC is dosed appropriately without affecting patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|